Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 12;12(2):429. doi: 10.3390/cancers12020429

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Knockdown of ABCG2 re-sensitizes resistant cells to MLN4924 treatment. (A) Knockdown of ABCG2 in MLN4924-resistant cells. A2780/MLN-R cells were infected with non-target control or ABCG2 lentiviral shRNA and positively infected cells were selected with puromycin. Immunoblotting confirmed knockdown of ABCG2 in the resistant cells. (B) Knockdown of ABCG2 re-sensitizes resistant cells to MLN4924. A2780/MLN-R cells were infected with control or ABCG2 lentiviral shRNA and were treated with the indicated concentrations of MLN4924 for 72 h. Cell viability was determined by MTT assay. Mean ± SD, n = 3. * Indicates a significant difference compared to non-target control-transfected cells treated with the same concentration. p < 0.05. (C) Diminished ABCG2 expression sensitizes resistant cells to MLN4924-mediated apoptosis. A2780/MLN-R cells infected with control or ABCG2 lentiviral shRNA were treated with 10 μM MLN4924 for 48 h. Apoptosis was determined by measuring active caspase-3 by flow cytometry and PI-FACS analysis. Mean ± SD, n = 3. * Indicates a significant difference from shRNA control MLN4924-treated cells.